U.S. markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.48
    -1.16 (-1.91%)
     
  • Gold

    1,737.10
    +14.10 (+0.82%)
     
  • Silver

    26.85
    +0.17 (+0.64%)
     
  • EUR/USD

    1.2096
    +0.0036 (+0.30%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3958
    +0.0038 (+0.27%)
     
  • USD/JPY

    106.6630
    -0.0670 (-0.06%)
     
  • BTC-USD

    47,559.54
    -1,033.84 (-2.13%)
     
  • CMC Crypto 200

    950.02
    -36.63 (-3.71%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Should You Get Rid of Forward Pharma (FWP) Now?

Zacks Equity Research

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Forward Pharma A/S FWP, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in FWP.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.05 a share a month ago to its current level of a loss of $1.31.

Also, for the current quarter, Forward Pharma has seen 1 downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 33 cents a share from a loss of 24 cents over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 10.7% in the past month.

FORWARD PHARMA Price and Consensus
 

FORWARD PHARMA Price and Consensus | FORWARD PHARMA Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical – Drugs industry, you may instead consider a better-ranked stock - Corcept Therapeutics Incorporated CORT. The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CORCEPT THERAPT (CORT): Free Stock Analysis Report
 
FORWARD PHARMA (FWP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research